With the lawsuit against Biontech and Pfizer, Moderna wants to protect its mRNA technology platform.
(Photo: AP)
Frankfurt The US biotech company Moderna wants to hold its German rival Biontech and its partner Pfizer accountable for alleged patent infringements in the development of corona vaccines. Moderna has therefore filed lawsuits in courts in the United States and Germany, the company announced on Friday. Moderna is demanding compensation for infringements of intellectual property rights, but has not yet disclosed the amount.
Specifically, it is about the development of mRNA vaccine against Covid-19. Moderna had already invested “billions of dollars” here before the outbreak of the pandemic and wanted to protect its innovative technology platform, CEO Stephane Bancel said, according to a press release.
Moderna is considered a pioneer in mRNA vaccines. The company already applied for patents in the years 2010 to 2016 – long before the pandemic caused the demand for vaccines to increase rapidly worldwide. However, the US company made it clear that it was not about having Biontech and Pfizer’s Comirnaty vaccine removed from the market.
The lawsuits do not relate to patent infringements before March 8, 2022, when Moderna announced, among other things, that it would not enforce patent protection for its vaccine as long as it was manufactured exclusively for use in 92 low- and middle-income countries.
Top jobs of the day
Find the best jobs now and
be notified by email.
Patent lawsuits related to vaccine development are not uncommon. Biontech and Pfizer are also facing allegations from other competitors. In July, the Tübingen-based biotech company Curevac, which had failed to develop its own corona vaccine, launched a legal dispute against Biontech and two subsidiaries.
In the process, it must be clarified to what extent the respective patents went into the development of the Biontech vaccine, said Curevac boss Franz-Werner Haas at the time. Biontech said the company’s work is “original and we will vigorously defend it against all allegations of patent infringement.”
The business with corona vaccines is very lucrative for companies thanks to the enormous demand in the pandemic. Moderna, for example, made a net profit of $2.2 billion on sales of $4.7 billion in the most recent quarter. The company expects vaccine sales of around $21 billion for the current 2022 fiscal year based on purchase agreements that have already been concluded.
However, Moderna also invested a lot of money in research and development before the Covid vaccine became a billion dollar business due to the pandemic. Pfizer also benefited greatly in the past quarter from its corona vaccine Comirnaty, which was developed and marketed together with Biontech.
More: Biontech could deliver first Omicron vaccine “early September”.